Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Mechanism of Action Trial of ColoAd1 (MOA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02053220
Recruitment Status : Completed
First Posted : February 3, 2014
Last Update Posted : March 12, 2020
Information provided by (Responsible Party):
PsiOxus Therapeutics Ltd

Brief Summary:
To assess the pattern of ColoAd1 viral delivery and viral expression within colon tumour tissue when administered by intra-tumoural injection or within colon, non-small cell lung, bladder and renal cell tumour tissues following ColoAd1 administration by intravenous infusion.

Condition or disease Intervention/treatment Phase
Resectable Colon Cancer Resectable Non-small Cell Lung Cancer Resectable Bladder Cancer Resectable Renal Cell Carcinoma Biological: Colo-Ad1 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Clinical Study of Intra-tumoural Injection or Intravenous Infusion of a Group B Oncolytic Adenovirus (ColoAd1) in Patients With Cancer Who Are Candidates for Resection of Primary Tumour
Study Start Date : June 2013
Actual Primary Completion Date : April 2015
Actual Study Completion Date : April 2016

Arm Intervention/treatment
Experimental: Intra-tumoural cohort Biological: Colo-Ad1
Oncolytic virus

Experimental: Intra-venous cohort Biological: Colo-Ad1
Oncolytic virus

Primary Outcome Measures :
  1. Composite measure of viral delivery and spread [ Time Frame: Up to Day 25 ]
    To assess the pattern of viral delivery and viral spread of ColoAd1 within tumour tissue when administered either by intra-tumoural injection or by intravenous infusion. Viral delivery and spread will be measured by immunohistochemical staining for ColoAd1 in tumour sections taken from patients. Presence of virus will also be detected by qPCR analysis of tumour tissue.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

Patients must meet all the following criteria to be eligible for participation:

  • Able and willing to provide written informed consent and to comply with the study protocol
  • Age ≥ 18 years
  • Patients with histologically confirmed resectable colon cancer, NSCLC (squamous and non-squamous), bladder cancer (urothelial cell carcinoma) or RCC (renal cell carcinoma), scheduled for resection of primary tumour and with planned resection of draining lymph nodes for colon cancer
  • Diagnostic colonoscopy performed at the study centre (Cohorts A and B only) or a referral centre (Cohort B only) and a report from this colonoscopy available for the study
  • Tumour size of 3 cm or more in diameter as estimated during diagnostic colonoscopy for cohorts A and B or by CT-scan for cohorts C, D and E.
  • At least 2 weeks since the last dose of any intravenous systemic chemotherapy at time of first administration of ColoAd1
  • Recovered to Grade 1 from the effects (excluding alopecia) of any prior therapy for their malignancies.
  • Able to undergo surgery with general anaesthesia
  • Surgery planned and administration of ColoAd1 feasible within

    • 15 days of planned surgery (following IT administration or following first dose of IV administration) for cohorts A and B
    • 10 - 25 days of first ColoAd1 administration for cohorts C, D and E
  • ECOG Performance Status Score of 0 or 1
  • Adequate renal function

    • Creatinine ≤ 1.5 mg/dL or calculated creatinine clearance using the Cockcroft-Gault formula ≥ 60 mL/min, or measured creatinine clearance ≥60 mL/min,
    • Absence of clinically significant haematuria on urinalysis: dipstick < 2+
    • Absence of clinically significant proteinuria on urinalysis: dipstick < 2+.
  • Adequate hepatic function

    • serum bilirubin <1.5 x ULN
    • AST and ALT ≤ 3 x ULN
  • Adequate bone marrow function:

    • ANC ≥ 1.5 x 109/L,
    • platelets ≥ 100 x 109/L,
    • haemoglobin ≥ 90 g/L
  • Adequate coagulation tests: INR ≤ 1.5 x ULN;
  • For females of childbearing potential (defined as <2 years after last menstruation or not surgically sterile), a negative pregnancy test must be documented prior to enrolment;
  • For women who are not postmenopausal (24 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception, including at least one method with a failure rate of < 1% per year (e.g., hormonal implants, combined oral contraceptives, vasectomized partner), during the treatment period and for at least 3 months after the last dose of study drug;
  • For men: agreement to use a barrier method of contraception during the treatment period and for at least 6 months after the last dose of study drug

Exclusion Criteria for all patients:

Patients who meet any of the following criteria are not eligible for enrolment:

  • Rectal tumours; (cohorts A and B);
  • An obstructive tumour of the intestine (cohorts A and B only) or of the urinary tract (cohort D);
  • Any condition necessitating surgery in less than 8 days (cohorts A or B) or 10 days (cohorts C, D or E);
  • Pregnant or lactating (nursing) women;
  • Known and/or a history or evidence of significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or medication (e.g. systemic corticosteroids at doses higher than dexamethasone 10 mg or equivalent, or other immunosuppressive medications including cyclosporine, azathioprine, interferons, within the past 4 weeks);
  • Splenectomy
  • Prior allogeneic or autologous bone marrow or organ transplantation
  • Active infections requiring antibiotics, physician monitoring, or recurrent fevers >38.0 degrees centigrade associated with a clinical diagnosis of active infection
  • Active viral disease, positive serology for HIV, hepatitis B or hepatitis C
  • Use of the following anti-viral agents:

    • ribavirin, adefovir, lamivudine or cidofovir within 7 days prior to day 1;
    • or PEG-IFN (within 14 days prior to day 1);
  • Administration of an investigational drug within 28 days prior to first dose of ColoAd1
  • Major surgery within 4 weeks or radiotherapy within 3 weeks prior to first dose of ColoAd1
  • Another primary malignancy within the past 3 years (except for non-melanoma skin cancer or cervical cancer in situ)
  • Known CNS metastasis
  • Inflammatory diseases of the bowel (cohorts A and B only) or any inflammatory disease that may require treatment with corticosteroids.
  • Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise patient safety or interfere with the evaluation of the safety of the drug
  • Known allergy to treatment medication or its excipients
  • Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02053220

Layout table for location information
Hospital Universitario Madrid Sanchinarro CIOCC
Madrid, Spain
Hospital Universitario Virgen del Rocío
Seville, Spain
Sponsors and Collaborators
PsiOxus Therapeutics Ltd
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: PsiOxus Therapeutics Ltd Identifier: NCT02053220    
Other Study ID Numbers: ColoAd1-1002
First Posted: February 3, 2014    Key Record Dates
Last Update Posted: March 12, 2020
Last Verified: March 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Neoplasms by Site
Urologic Neoplasms
Urogenital Neoplasms
Urologic Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Kidney Diseases